SEC Form 4 · accession 0001808365-26-000002
Keros Therapeutics, Inc. · KROS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julius Knowles
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001664710
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 3, 2026 | A | 7,142 | $0.00 | A | 13,583 | D | |
| Common StockF2 | holding | — | — | — | 150,047 | I | See footnote | |
| Common StockF3 | holding | — | — | — | 102,233 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $10.50 | Jun 3, 2026 | A | 7,433 | A | — | Jun 2, 2036 | Common Stock | 7,433 | 7,433 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
- F2The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
- F3The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
- F4The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.